exp date isn't null, but text field is
The principle of this document is to provide practical guidance for CF patient accommodation, appointments and movement throughout RHC which follows GGC IPC SOP advice.
Cystic fibrosis is a life-limiting disease, the outcome of which has improved significantly over the years. Progression of lung disease may be associated with certain respiratory bacteria, particularly Pseudomonas aeruginosa, Burkholderia species and Nontuberculous mycobacteria. Avoiding lung colonisation with these organisms is expected (although not proven) to improve life expectancy. The Cystic Fibrosis community has produced useful documents about these organisms. 2
STAPHYLOCOCCUS AUREUS
HAEMOPHILUS INFLUENZAE
PSEUDOMONAS AERUGINOSA
Conclusion:
BURKHOLDERIA SPECIES
Conclusion:
NON-TUBERCULOUS MYCOBACTERIA (NTM)
MULTI-RESISTANT ORGANISMS
ORGANISM |
CLEAR IF -VE |
Pseudomonas aeruginosa |
6 months unless more than 2 eradication episodes in which case 12 months |
Burkholderia species |
12 months |
NTM- Any |
12 months with 3 –ve samples taken OFF Azithromycin |
Other Multiresistant CF Pathogens [MROther ] |
|
• MRSA |
12 MONTHS |
• Pandorea |
12 MONTHS |
• Achromobacter |
12 MONTHS |
• S. maltophilia |
12 MONTHS |
• Other Pseudomonas species |
6 MONTHS |
The GGC IPC Team has produced SOPs relating to CF patients attending RHC Inpatient and Outpatient departments. While adherence to the IPC advice in these SOPs allows for most CF patients to be seen in any Microbiology status order, exceptions to this are shown in the Table below which highlights the most significant pathogenic CF organisms.
Order |
|
Microbiology Status |
1 |
Multiresistant CF pathogens* ( see above) apart from Pseudomonas, Burkholderia, or any NTM – Microbiology status [MROther] |
|
2 |
Pseudomonas aeruginosa- Microbiology status [CI/CI*/CC] |
|
3 |
Burkholderia Species – Microbiology status [BC / BS ] |
|
4 |
Any Non-tuberculous Mycobacteria except M abscessus Microbiology status [ MROther NTM] |
|
5 |
M abscessus – Microbiology status [MROther NTM M abscessus] |
CLINICS
NON-CF CLINIC APPOINTMENTS / OTHER VISITS TO RHC
Cystic Fibrosis patients are admitted to one of 4 Designated Wards in RHC- 3A,3B,3C,2C(ARU) - as per Microbiology Status displayed as an Alert on Trakcare. If there is a clinical requirement for a CF patient to be nursed in another Ward e.g. Renal, Surgical, Cardiac, this will be managed on an individual basis and CF IPC SOP policies adhered to.
WARD 3B: (N / NI / NMROther / NIMROther ) |
WARD 3A: (CI /CI*/ CI MR/ CI*MR/ CC / CCMR / CI MROther/ CI*MROther/ CCMROther ) |
WARD 2C (ARU): (BC / BS) |
WARD 3C: ANY NTM |
ENSURING A UNIFORM STANDARD OF CARE IN EACH WARD
A Cystic Fibrosis Care Plan is available for Staff to follow. This is available in hard copy format on each Ward and is maintained by the CF Sisters. When possible, the Cystic Fibrosis Nurse Specialists ensure that there are regular teaching sessions about Cystic Fibrosis for the nurses on the each of the different wards.
ACCESS FOR VISITORS/CARERS
GROUP ACTIVITIES WITHIN RHC
For infection control reasons patients with CF should not be taken to Hospital Group Activities or communal patient areas such as Medicinema, Play Areas (including within the RHC Atrium), School Room, Radio Lollipop, Shops, Coffee Bars or Restaurants, etc
Arrangements must be in place to ensure that CF patients do not mix in waiting areas of other departments. Ward Staff should contact individual Departments to check that no other CF patients are currently attending that Department.
Arrangements will be made to ensure that CF patients do not mix in the admission or recovery areas of theatres. Patients with multi-resistant organisms should be placed at the end of the appropriate theatre list.
All staff should familiarise themselves with this policy and relevant GGC IPC SOPs.
OUTPATIENTS
INPATIENTS
OUTPATIENTS
INPATIENTS
Last reviewed: 22 December 2020
Next review: 22 December 2022
Author(s): Dr Jane Wilkinson; Dr Christine Peters; Dr Anne Devenny; Linda Cassidy
Version: 2
Approved By: Paediatric Clinical Risk & Effectiveness Committee